Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors - Contacts and Locations

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

This study has been withdrawn prior to recruitment.

Study NCT00072228. Last updated on December 4, 2006. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00072228

Locations


United States, New Mexico
	University of New Mexico Cancer Research and Treatment Center
	Albuquerque, New Mexico, United States, 87131-5636

United States, New York
	Herbert Irving Comprehensive Cancer Center at Columbia University
	New York, New York, United States, 10032

Sponsors and Collaborators

Daiichi Pharmaceuticals

Investigators


Study Chair:	Robert L. DeJager, MD, FACP	Daiichi Pharmaceuticals